StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Progress in dose escalation and timely readouts often improves perceived program momentum, potentially supporting TRDA shares if safety data remain favorable and interim efficacy signals emerge.
What happened, with direct paths to the underlying reporting
Entrada Therapeutics announced that an independent Data Monitoring Committee reviewed safety and PK data from eight Cohort 2 participants and recommended initiating Cohort 3 at 18 mg/kg. Cohort 2 enrollment is complete, with data expected in Q1 2027; Cohort 1 open-label data are due by year-end 2026. These developments mark near-term trial progression catalysts for TRDA’s Elevate-44-201 program.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.